JPRN-jRCT1021210009招募中4 期
The safety and efficacy of COVID-19 vaccines among lung transplant recipients: Non-randomised controlled cohort study - The safety and efficacy of COVID-19 vaccines among lung transplant recipients
Okada Yoshinori0 个研究点目标入组 80 人开始时间: 2021年6月4日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Lung transplant recipients followed at Tohoku University Hospital who fulfilled the following criteria 1-5:
- •(1) 6 months after lung transplant
- •(2) two-time COVID-19 vaccination
- •(3) no history of COVID-19 infection
- •(4) 20 years old or above
- •(5) written informed consent obtained
- •Controls followed at Tohoku University Hospital or Tohoku Kosai Hospital who fulfilled the following criteria 1-4:
- •(1) no history of transplantation and immunosuppressive therapy
- •(2) two-time COVID-19 vaccination
- •(3) no history of COVID-19 infection
- •(4) 20 years old or above
- •(5) written informed consent obtained
排除标准
- •(1) informed consent unobtained
- •(2) aged 19 years old or below
研究者
相似试验
招募中
不适用
Safety profile of COVID-19 vaccines and the comparison to COVID-19 symptomatologyZ20.8U07.1Contact with and exposure to other communicable diseasesCOVID-19, virus identifiedDRKS00024800Charité - Universitätsmedizin Berlin7,800
已完成
4 期
The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplantNL-OMON51071niversitair Medisch Centrum Groningen850
进行中（未招募）
1 期
The efficacy and safety of COVID-19 vaccination in patients with a kidney diseaseCOVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccination would be of great clinical importance in these patients.However, SARS-CoV-2 vaccination studies have excluded KTR and patients with CKD so-far. This will be the subject of this trial.MedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10061105Term: DialysisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084462Term: SARS-CoV-2 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084463Term: SARS-CoV-2 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-000868-30-NLRECOVAC consortium850
进行中（未招募）
不适用
Immunogenicity and safety of COVID-19 vaccines in SLE and rheumatoid arthritis patientsSLERAImmunosuppresive agentsImmunogenicity to SARS-CoV2 vaccinationSLEImmunosuppressive therapyHumoral immune responseCellular immune responseSARS-CoV-2 vaccineRATCTR20210917003Ratchadapiseksompotch Fund, Faculty of Medicine100
已完成
1 期
Safety and Immunogenicity of EXG-5003.Prevention for SARS-CoV-2 infection diseaseJPRN-jRCT2041210013Doi Yohei60